Glioblastoma as a Novel Drug Repositioning Target: Updated State.

Détails

ID Serval
serval:BIB_4FA0BE686C77
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Glioblastoma as a Novel Drug Repositioning Target: Updated State.
Périodique
Anti-cancer agents in medicinal chemistry
Auteur⸱e⸱s
Hosseinalizadeh H., Ebrahimi A., Tavakoli A., Monavari S.H.
ISSN
1875-5992 (Electronic)
ISSN-L
1871-5206
Statut éditorial
Publié
Date de publication
2023
Peer-reviewed
Oui
Volume
23
Numéro
11
Pages
1253-1264
Langue
anglais
Notes
Publication types: Review ; Journal Article
Publication Status: ppublish
Résumé
Glioblastoma multiforme (GBM) is an aggressive form of adult brain tumor that can arise from a low-grade astrocytoma. In recent decades, several new conventional therapies have been developed that have significantly improved the prognosis of patients with GBM. Nevertheless, most patients have a limited long-term response to these treatments and survive < 1 year. Therefore, innovative anti-cancer drugs that can be rapidly approved for patient use are urgently needed. One way to achieve accelerated approval is drug repositioning, extending the use of existing drugs for new therapeutic purposes, as it takes less time to validate their biological activity as well as their safety in preclinical models. In this review, a comprehensive analysis of the literature search was performed to list drugs with antiviral, antiparasitic, and antidepressant properties that may be effective in GBM and their putative anti-tumor mechanisms in GBM cells.
Mots-clé
Adult, Humans, Glioblastoma/drug therapy, Glioblastoma/pathology, Drug Repositioning, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Prognosis, Brain Neoplasms/drug therapy, Brain Neoplasms/pathology, GBM, Glioblastoma, blood-brain barrier, brain tumor, drug repositioning, non-cancer drugs
Pubmed
Web of science
Création de la notice
13/02/2023 17:07
Dernière modification de la notice
19/10/2023 6:10
Données d'usage